Pharmamarketeer
wet- en regelgeving

Vertex’s Orkambi receives European approval to treat children with CF aged 2 to 5 years old with most common form of disease

22 januari 2019
Pharma Biz

Vertex Pharmaceuticals Limited announced that the European Commission has granted approval of the label extension for Orkambi (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF)

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)